TY - JOUR
T1 - Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein
AU - Dallinga-Thie, G. M.
AU - van Tol, A.
AU - Dullaart, R. P. F.
PY - 2009
Y1 - 2009
N2 - Atorvastatin lowers plasma phospholipid transfer protein (PLTP) activity,which stimulates pre-beta HDL generation in vitro. We determined the effect of atorvastatin on pre-beta HDL formation and its relation with PLTP activity in type 2 diabetes. METHODS: Plasma pre-beta HDL formation as well as plasma apoA-I, LpA, LpAI:AII, cholesteryl ester transfer protein (CETP) and PLTP activity were measured before and after 30 weeks treatment in 40 patients randomized to atorvastatin 80 mg daily and 41 placebo receiving patients. Pre-beta HDL formation was measured by crossed immunoelectrophoresis under conditions of lecithin:cholesterol acyltransferase (LCAT) inhibition. RESULTS: Plasma pre-beta HDL formation, triglycerides, LDL cholesterol, PLTP activity, and CETP decreased after statin treatment (all P <0.001 vs. placebo), whereas HDL cholesterol increased (P <0.005). Plasma apo A-I, Lp-AI and LpAI:AII remained unchanged compared to placebo. In all patients combined, the changes in pre-beta HDL formation were independently related to the decrease in plasma triglycerides (beta=0.31; P=0.006) and PLTP activity (beta=0.23; P=0.038), without a contribution of CETP. In the atorvastatin treated patients, the decrease in pre-beta HDL formation tended to related to the decrease in PLTP activity (beta=0.30, P=0.061) after controlling for decreases in triglycerides (beta=0.22, P=0.22). CONCLUSION: High dose atorvastatin decreases the capacity of plasma to generate pre-beta HDL particles in type 2 diabetic patients, probably via lowering of plasma PLTP activity and triglycerides. This could contribute to an improvement in the atherogenic lipoprotein profile
AB - Atorvastatin lowers plasma phospholipid transfer protein (PLTP) activity,which stimulates pre-beta HDL generation in vitro. We determined the effect of atorvastatin on pre-beta HDL formation and its relation with PLTP activity in type 2 diabetes. METHODS: Plasma pre-beta HDL formation as well as plasma apoA-I, LpA, LpAI:AII, cholesteryl ester transfer protein (CETP) and PLTP activity were measured before and after 30 weeks treatment in 40 patients randomized to atorvastatin 80 mg daily and 41 placebo receiving patients. Pre-beta HDL formation was measured by crossed immunoelectrophoresis under conditions of lecithin:cholesterol acyltransferase (LCAT) inhibition. RESULTS: Plasma pre-beta HDL formation, triglycerides, LDL cholesterol, PLTP activity, and CETP decreased after statin treatment (all P <0.001 vs. placebo), whereas HDL cholesterol increased (P <0.005). Plasma apo A-I, Lp-AI and LpAI:AII remained unchanged compared to placebo. In all patients combined, the changes in pre-beta HDL formation were independently related to the decrease in plasma triglycerides (beta=0.31; P=0.006) and PLTP activity (beta=0.23; P=0.038), without a contribution of CETP. In the atorvastatin treated patients, the decrease in pre-beta HDL formation tended to related to the decrease in PLTP activity (beta=0.30, P=0.061) after controlling for decreases in triglycerides (beta=0.22, P=0.22). CONCLUSION: High dose atorvastatin decreases the capacity of plasma to generate pre-beta HDL particles in type 2 diabetic patients, probably via lowering of plasma PLTP activity and triglycerides. This could contribute to an improvement in the atherogenic lipoprotein profile
U2 - https://doi.org/10.1016/j.bbalip.2009.03.008
DO - https://doi.org/10.1016/j.bbalip.2009.03.008
M3 - Article
C2 - 19303940
SN - 1388-1981
VL - 1791
SP - 714
EP - 718
JO - BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
JF - BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
IS - 8
ER -